RA Capital Management, an investment company, led a $60m Series A round in Lusaris Therapeutics, a biotechnology company, with participation from Venrock Healthcare Capital Partners, Deep Track Capital, Boxer Capital. “We aim to develop best-in-class neurotherapeutics that have the potential to reach more patients in need by decreasing the treatment burden on both patients and physicians. With encouraging preclinical data, a proven delivery technology, and an expected rapid and short psychotropic experience, LSR-1019 has the potential to be a transformative treatment for patients suffering from TRD and other serious mood disorders,” Neil Buckley, Lusaris Chief Operating Officer.